<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847639</url>
  </required_header>
  <id_info>
    <org_study_id>07-REV</org_study_id>
    <nct_id>NCT00847639</nct_id>
  </id_info>
  <brief_title>Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma</brief_title>
  <acronym>07-REV</acronym>
  <official_title>Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High-risk Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for International Blood and Marrow Transplant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for International Blood and Marrow Transplant Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-institution, non-randomized, open label, Phase IIa prospective trial to&#xD;
      evaluate the safety and tolerability of maintenance lenalidomide after allogeneic&#xD;
      hematopoietic stem cell transplantation (HCT).&#xD;
&#xD;
      Lenalidomide maintenance therapy will start between day 60 and 90 after allogeneic HCT at a&#xD;
      starting dose of 10mg PO once daily. Dose escalation and de-escalation will be performed&#xD;
      depending on tolerability of lenalidomide. Dose range is 5mg every other day to 5 - 25 mg&#xD;
      given daily on days 1-21 of a 28-day cycle for 12 cycles maximum or maximum of 12 months from&#xD;
      first dose of study drug.&#xD;
&#xD;
      Patients will be followed until 28 days from completing the 12th planned cycle of&#xD;
      lenalidomide maintenance or 12 months from first dose of study drug, which ever comes first,&#xD;
      (14 to 15 months after receiving the allograft) or discontinuation of study drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine tolerability and safety profile of a maximum of 12 cycles or 12 months from first dose (which ever comes first) of lenalidomide maintenance therapy post allogeneic hematopoietic cell transplantation for high risk multiple myeloma.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the incidences of ≥ grade 3 adverse events, graft failure, infections, treatment-related mortality (TRM) and incidence and severity of acute and chronic GVHD after initiation of lenalidomide.</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the overall response and best response rates to lenalidomide maintenance therapy following allogeneic HCT.</measure>
    <time_frame>13 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine time to disease progression and overall survival after lenalidomide.</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide maintenance therapy will start within 60 to 180 days after allogeneic HCT at a starting dose of 10mg PO once daily. Dose escalation and de-escalation are performed depending on tolerability of lenalidomide. The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.&#xD;
Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.&#xD;
The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  One prior allograft from an 8/8 or 7/8 allele matched related or unrelated donor,&#xD;
             received 60 to 90 days prior to initiation of lenalidomide&#xD;
&#xD;
          -  Meet the diagnostic criteria of symptomatic myeloma at anytime prior to allogeneic HCT&#xD;
&#xD;
          -  Have high-risk multiple myeloma&#xD;
&#xD;
          -  Received ≤ three (3) prior lines of therapy. Prior therapies may include: combination&#xD;
             chemotherapy, monotherapy, lenalidomide and autologous HCT. Localized radiation&#xD;
             therapy does not count as a single line of therapy. Previous progression on&#xD;
             lenalidomide does not exclude participation in the study.&#xD;
&#xD;
          -  Received a reduced intensity conditioning regimen&#xD;
&#xD;
          -  Received or are receiving a GVHD prophylaxis regimen of a calcineurin inhibitor in&#xD;
             combination with either methotrexate, mycophenolate mofetil (MMF) or sirolimus&#xD;
&#xD;
          -  Karnofsky performance score ≥ 80 or ECOG ≤ 2&#xD;
&#xD;
          -  There must be at least 50% donor chimerism and no evidence of falling donor chimerism&#xD;
             within 1 month of enrollment&#xD;
&#xD;
          -  Laboratory test results within range, within 14 days prior to initiation of&#xD;
             lenalidomide&#xD;
&#xD;
          -  All study participants must be registered into the mandatory RevAssist® program, and&#xD;
             be willing and able to comply with the requirements of RevAssist®.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease progression at time of study entry&#xD;
&#xD;
          -  Patients with any grade III-IV GVHD at the time of study entry&#xD;
&#xD;
          -  Patients requiring additional immunosuppressive therapy to control acute GVHD other&#xD;
             than corticosteroids and immunosuppressive agents used for prophylaxis.&#xD;
&#xD;
          -  Concomitant use of other investigational agents&#xD;
&#xD;
          -  Patients who have received donor lymphocyte infusions&#xD;
&#xD;
          -  Active CNS malignancy&#xD;
&#xD;
          -  Uncontrolled bacterial, viral, or fungal infections&#xD;
&#xD;
          -  Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma&#xD;
             in situ &lt; 5 years from study entry.&#xD;
&#xD;
          -  Known hypersensitivity or desquamating rash to either thalidomide or lenalidomide.&#xD;
&#xD;
          -  Known positive for HIV or active infectious hepatitis.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,&#xD;
             severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute&#xD;
             ischemia or active conduction system abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Alsina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcelo Pasquini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CIBMTR/ Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Allogeneic Hematopoietic Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

